Download PDF
Ernährung & Medizin 2020; 35(03): 105-106
DOI: 10.1055/a-0971-0632
Seitenblicke

Vitamin D und Hodgkin-Lymphome

Onkologie
› Further Information
    Permissions and Reprints

Borchmann S, Cirillo M, Goergen H et al. Pretreatment vitamin D deficiency is associated with impaired progression-free and overall survival in Hodgkin lymphoma. J Clin Oncol 2019; 37: 3528–3537

Ziel einer Studie von Kölner Forschern war es, herauszufinden, ob ein Vitamin-D-Mangel bei Hodgkin-Lymphom-Patienten mit einer schlechteren Tumorkontrolle und mit einem schlechteren progressionsfreien Überleben und Gesamtüberleben verbunden ist.



Publication History

Article published online:
10 September 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Bittenbring JT, Neumann F, Altmann B. et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 2014; 32: 3242-3248
    CrossrefPubMedGoogle Scholar
  • 2 McDonnell SL, Baggerly C, French CB. et al. Serum 25-hydroxyvitamin D concentrations > / = 40 ng/ml are associated with > 65 % lower cancer risk: pooled analysis of randomized trial and prospective cohort study. PLoS One 2016; 11 (04) e0152441
    CrossrefPubMedGoogle Scholar
  • 3 McDonnell SL, Baggerly CA, French CB. et al. Breast cancer risk markedly lower with serum 25-hydroxyvitamin D concentrations > / = 60 vs < 20 ng/ml (150 vs 50 nmol/L): Pooled analysis of two randomized trials and a prospective cohort. PLoS One 2018; 13 (06) e0199265
    CrossrefPubMedGoogle Scholar
  • 4 Uwitonze AM, Razzaque MS. Role of magnesium in vitamin D activation and function. J Am Osteopath Assoc 2018; 118: 181-189
    CrossrefPubMedGoogle Scholar